세계의 단클론항체(mAb) 치료제 시장 동향 분석, 경쟁 상황, 예측(2019-2031년) : 유래별, 용도/치료 분야별, 유통 채널별, 지역별

Global Monoclonal Antibody (mAb) Therapeutics Market Zooming 2X to Touch USD 560 Billion by 2031

Global Monoclonal Antibody (mAb) Therapeutics Market is flourishing because of the rising incidence of chronic diseases, increasing investments in biopharma R&D programs, and the expanding therapeutic applications of mAbs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Monoclonal Antibody (mAb) Therapeutics Market size at USD 273.2 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Monoclonal Antibody (mAb) Therapeutics Market size to more than doubles at a robust CAGR of 11.2% reaching a value of USD 559.3 billion by 2031. The increasing prevalence of chronic diseases, including cancer and cardiovascular conditions, fuels demand for biologics like mAbs, particularly for targeted therapies. Growing awareness among both patients and healthcare providers regarding the efficacy of mAb treatments are also major driving forces behind the Global Monoclonal Antibody (mAb) Therapeutics Market. mAbs, generated from cell lines or clones derived from immunized animals, have become indispensable in modern medicine. Their ability to target specific disease markers and pathogens underpins their broad applicability. The COVID-19 pandemic, with the development of mAb treatments like Eli Lilly's bebtelovimab (which received FDA emergency use authorization), further accelerated the market momentum. The advantages of mAb therapies, including their specificity, effectiveness, and convenient delivery methods, have resulted in numerous product launches and approvals, with over 100 mAbs currently holding FDA approval. Ongoing innovations in various areas, such as antibody fragments, bispecific antibodies, and other advanced therapies, promises to broaden their therapeutic applications. Furthermore, strategic initiatives undertaken by key market players continue to propel the expansion of Global Monoclonal Antibody (mAb) Therapeutics Market.

Opportunity - Expanding Global Access to Monoclonal Antibodies

Monoclonal antibodies (mAbs) have revolutionized the treatment of cancers, autoimmune diseases, and infectious diseases like COVID-19 and HIV, but access remains limited, with 80% of sales concentrated in high-income regions while 85% of the global population resides in low- and middle-income countries. To address this gap, global health organizations such as IAVI and Wellcome have issued a call to action, urging stakeholders to raise awareness of mAbs' life-saving potential, expand their licensure, reduce production costs, and create innovative business models for sustainable access. Advancements in hybridoma technology, electrofusion, transgenic animals, and nucleic acid-based mAbs are enhancing production by improving specificity, reducing immunogenicity, and simplifying manufacturing. These innovations enable more precise treatments with fewer side effects, targeting specific antigens on cancer and other unwanted cells. As the mAb market grows, increasing accessibility will be crucial in ensuring these transformative therapies are equitably distributed, maximizing their global impact.

Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

Intensifying geopolitical tensions could disrupt the growth of Global Monoclonal Antibody (mAb) Therapeutics Market. Potential disruptions, including trade restrictions, increased tariffs, supply chain vulnerabilities, and fluctuating regulatory environments, could impede mAb production and distribution, potentially increasing costs and restricting patient access, while also negatively impacting international pharmaceutical collaborations and investments in biologic drug development. Conversely, these tensions may stimulate increased government focus on healthcare security and the development of domestic biopharmaceutical manufacturing capacity, potentially bolstering regional production, reducing import reliance, and fostering innovation in supply chain resilience and alternative manufacturing strategies. Thus, while geopolitical uncertainties pose significant challenges, they may also inadvertently drive advancements and reshape the future trajectory of Global mAb Therapeutics Market.

North America Leads Global Monoclonal Antibody (mAb) Therapeutics Market

North America commands the leading position in Global Monoclonal Antibody (mAb) Therapeutics Market, primarily fueled by substantial healthcare expenditures, particularly in the United States. While United States healthcare spending significantly outpaces that of other nations, this expenditure does not consistently translate into proportionally improved health outcomes. High service prices and utilization rates contribute to the escalating costs within the United States system. Concurrently, Canada's medical sector is experiencing robust growth, driven by innovative research, technological advancements, and increasing demand for healthcare services. This dynamic evolution of the Canadian healthcare landscape further strengthens North America's overall market dominance and growth potential in the mAb therapeutics arena. Illustrating this market activity, in January 2022, GSK and Vir Biotechnology secured a significant agreement with the United States government for the purchase of additional supplies of sotrovimab, a mAb authorized for early treatment of COVID-19.

Competitive Landscape

Major companies in Global Monoclonal Antibody (mAb) Therapeutics Market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Monoclonal Antibody (mAb) Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Monoclonal Antibody (mAb) Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Monoclonal Antibody (mAb) Therapeutics Market Insights

• 3.1. End User Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Prevalence of Chronic Diseases
    • 3.2.1.2. Growing Investments in (mAb) R&D Programs
    • 3.2.1.3. Expanding Applications
  • 3.2.2. Restraints
    • 3.2.2.1. High Cost of (mAb) Therapies
    • 3.2.2.2. Stringent Regulatory Requirements
  • 3.2.3. Opportunities
    • 3.2.3.1. Developing Novel (mAb) Therapies
    • 3.2.3.2. Growing Adoption of Personalized Medicines
  • 3.2.4. Challenges
    • 3.2.4.1. Competitions from Biosimilars
    • 3.2.4.2. Potential Side Effects
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Monoclonal Antibody (mAb) Therapeutics Market: Marketing Strategies

5. Global Monoclonal Antibody (mAb) Therapeutics Market: Pricing Analysis

6. Global Monoclonal Antibody (mAb) Therapeutics Market: Geography Analysis

• 6.1. Global Monoclonal Antibody (mAb) Therapeutics Market, Geographical Analysis, 2024
• 6.2. Global Monoclonal Antibody (mAb) Therapeutics, Market Attractiveness Analysis, 2024-2031

7. Global Monoclonal Antibody (mAb) Therapeutics Market Overview

• 7.1. Market Size & Forecast, 2019-2031
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
    • 7.2.1.1. Human
    • 7.2.1.2. Humanized
    • 7.2.1.3. Chimeric
    • 7.2.1.4. Murine
  • 7.2.2. By Application/Therapy Area
    • 7.2.2.1. Oncology
    • 7.2.2.2. Autoimmune Diseases
    • 7.2.2.3. Infectious Diseases
    • 7.2.2.4. Hematological Disorders
    • 7.2.2.5. Cardiovascular Diseases
    • 7.2.2.6. Others
  • 7.2.3. By Distribution Channel
    • 7.2.3.1. Hospitals
    • 7.2.3.2. Retail Pharmacies
    • 7.2.3.3. Online Pharmacies
  • 7.2.4. By Region
    • 7.2.4.1. North America
    • 7.2.4.2. Europe
    • 7.2.4.3. Asia Pacific (APAC)
    • 7.2.4.4. Latin America (LATAM)
    • 7.2.4.5. Middle East and Africa (MEA)

8. North America Monoclonal Antibody (mAb) Therapeutics Market

• 8.1. Market Size & Forecast, 2019-2031
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.1.1. By Source
    • 8.2.4.1.2. By Application
    • 8.2.4.1.3. By Distribution Channel
    • 8.2.4.2. Canada
    • 8.2.4.2.1. By Source
    • 8.2.4.2.2. By Application
    • 8.2.4.2.3. By Distribution Channel

9. Europe Monoclonal Antibody (mAb) Therapeutics Market

• 9.1. Market Size & Forecast, 2019-2031
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
    • 9.2.4.1. Germany
    • 9.2.4.1.1. By Source
    • 9.2.4.1.2. By Application
    • 9.2.4.1.3. By Distribution Channel
    • 9.2.4.2. United Kingdom
    • 9.2.4.2.1. By Source
    • 9.2.4.2.2. By Application
    • 9.2.4.2.3. By Distribution Channel
    • 9.2.4.3. Italy
    • 9.2.4.3.1. By Source
    • 9.2.4.3.2. By Application
    • 9.2.4.3.3. By Distribution Channel
    • 9.2.4.4. France
    • 9.2.4.4.1. By Source
    • 9.2.4.4.2. By Application
    • 9.2.4.4.3. By Distribution Channel
    • 9.2.4.5. Spain
    • 9.2.4.5.1. By Source
    • 9.2.4.5.2. By Application
    • 9.2.4.5.3. By Distribution Channel
    • 9.2.4.6. Belgium
    • 9.2.4.6.1. By Source
    • 9.2.4.6.2. By Application
    • 9.2.4.6.3. By Distribution Channel
    • 9.2.4.7. Russia
    • 9.2.4.7.1. By Source
    • 9.2.4.7.2. By Application
    • 9.2.4.7.3. By Distribution Channel
    • 9.2.4.8. The Netherlands
    • 9.2.4.8.1. By Source
    • 9.2.4.8.2. By Application
    • 9.2.4.8.3. By Distribution Channel
    • 9.2.4.9. Rest of Europe
    • 9.2.4.9.1. By Source
    • 9.2.4.9.2. By Application
    • 9.2.4.9.3. By Distribution Channel

10. Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market

• 10.1. Market Size & Forecast, 2019-2031
  • 10.1.1. By Value (USD Billion)
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
    • 10.2.4.1. China
    • 10.2.4.1.1. By Source
    • 10.2.4.1.2. By Application
    • 10.2.4.1.3. By Distribution Channel
    • 10.2.4.2. India
    • 10.2.4.2.1. By Source
    • 10.2.4.2.2. By Application
    • 10.2.4.2.3. By Distribution Channel
    • 10.2.4.3. Japan
    • 10.2.4.3.1. By Source
    • 10.2.4.3.2. By Application
    • 10.2.4.3.3. By Distribution Channel
    • 10.2.4.4. South Korea
    • 10.2.4.4.1. By Source
    • 10.2.4.4.2. By Application
    • 10.2.4.4.3. By Distribution Channel
    • 10.2.4.5. Australia and New Zealand
    • 10.2.4.5.1. By Source
    • 10.2.4.5.2. By Application
    • 10.2.4.5.3. By Distribution Channel
    • 10.2.4.6. Indonesia
    • 10.2.4.6.1. By Source
    • 10.2.4.6.2. By Application
    • 10.2.4.6.3. By Distribution Channel
    • 10.2.4.7. Malaysia
    • 10.2.4.7.1. By Source
    • 10.2.4.7.2. By Application
    • 10.2.4.7.3. By Distribution Channel
    • 10.2.4.8. Singapore
    • 10.2.4.8.1. By Source
    • 10.2.4.8.2. By Application
    • 10.2.4.8.3. By Distribution Channel
    • 10.2.4.9. Vietnam
    • 10.2.4.9.1. By Source
    • 10.2.4.9.2. By Application
    • 10.2.4.9.3. By Distribution Channel
    • 10.2.4.10. Rest of APAC
    • 10.2.4.10.1. By Source
    • 10.2.4.10.2. By Application
    • 10.2.4.10.3. By Distribution Channel

11. Latin America Monoclonal Antibody (mAb) Therapeutics Market

• 11.1. Market Size & Forecast, 2019-2031
  • 11.1.1. By Value (USD Billion)
• 11.2. Market Share & Forecast
  • 11.2.1. By Source
  • 11.2.2. By Application
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
    • 11.2.4.1. Brazil
    • 11.2.4.1.1. By Source
    • 11.2.4.1.2. By Application
    • 11.2.4.1.3. By Distribution Channel
    • 11.2.4.2. Mexico
    • 11.2.4.2.1. By Source
    • 11.2.4.2.2. By Application
    • 11.2.4.2.3. By Distribution Channel
    • 11.2.4.3. Argentina
    • 11.2.4.3.1. By Source
    • 11.2.4.3.2. By Application
    • 11.2.4.3.3. By Distribution Channel
    • 11.2.4.4. Peru
    • 11.2.4.4.1. By Source
    • 11.2.4.4.2. By Application
    • 11.2.4.4.3. By Distribution Channel
    • 11.2.4.5. Rest of LATAM
    • 11.2.4.5.1. By Source
    • 11.2.4.5.2. By Application
    • 11.2.4.5.3. By Distribution Channel

12. Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market

• 12.1. Market Size & Forecast, 2019-2031
  • 12.1.1. By Value (USD Billion)
• 12.2. Market Share & Forecast
  • 12.2.1. By Source
  • 12.2.2. By Application
  • 12.2.3. By Distribution Channel
  • 12.2.4. By Country
    • 12.2.4.1. Saudi Arabia
    • 12.2.4.1.1. By Source
    • 12.2.4.1.2. By Application
    • 12.2.4.1.3. By Distribution Channel
    • 12.2.4.2. UAE
    • 12.2.4.2.1. By Source
    • 12.2.4.2.2. By Application
    • 12.2.4.2.3. By Distribution Channel
    • 12.2.4.3. Qatar
    • 12.2.4.3.1. By Source
    • 12.2.4.3.2. By Application
    • 12.2.4.3.3. By Distribution Channel
    • 12.2.4.4. Kuwait
    • 12.2.4.4.1. By Source
    • 12.2.4.4.2. By Application
    • 12.2.4.4.3. By Distribution Channel
    • 12.2.4.5. South Africa
    • 12.2.4.5.1. By Source
    • 12.2.4.5.2. By Application
    • 12.2.4.5.3. By Distribution Channel
    • 12.2.4.6. Nigeria
    • 12.2.4.6.1. By Source
    • 12.2.4.6.2. By Application
    • 12.2.4.6.3. By Distribution Channel
    • 12.2.4.7. Algeria
    • 12.2.4.7.1. By Source
    • 12.2.4.7.2. By Application
    • 12.2.4.7.3. By Distribution Channel
    • 12.2.4.8. Rest of MEA
    • 12.2.4.8.1. By Source
    • 12.2.4.8.2. By Application
    • 12.2.4.8.3. By Distribution Channel

13. Competitive Landscape

• 13.1. List of Key Players and Their Offerings
• 13.2. Global Monoclonal Antibody (mAb) Therapeutics Company Market Share Analysis, 2024
• 13.3. Competitive Benchmarking, By Operating Parameters
• 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

14. Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 15.1. F. Hoffmann-La Roche Ltd
• 15.2. Novartis AG
• 15.3. Johnson & Johnson Services, Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. Merck & Co., Inc.
• 15.6. Amgen Inc
• 15.7. Bristol Myers Squibb Company (US)
• 15.8. Merck & Co Inc
• 15.9. AstraZeneca plc
• 15.10. Sanofi
• 15.11. Bayer AG
• 15.12. Eli Lilly and Company
• 15.13. Thermo Fisher Scientific Inc
• 15.14. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

• 17.1. Qualitative Research
  • 17.1.1. Primary & Secondary Research
• 17.2. Quantitative Research
• 17.3. Market Breakdown & Data Triangulation
  • 17.3.1. Secondary Research
  • 17.3.2. Primary Research
• 17.4. Breakdown of Primary Research Respondents, By Region
• 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable